Physician profile
Cara Daniel
NPI 1104831676
$971.11
in general payments reported to CMS, 2019-2025
24 companies · $332 in 2025
The $332 reported for 2025 was more than what 87% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2020: $26.53 · 2021: $30.23 · 2023: $139 · 2024: $265 · 2025: $332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $736.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $736.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $146.02 | 2023-2025 | Vraylar |
| Novo Nordisk INC | $102.68 | 2019-2025 | Wegovy |
| Otsuka America Pharmaceutical, INC. | $68.27 | 2024-2025 | Rexulti |
| Cranial Technologies, INC | $63.68 | 2023-2024 | Doc Band |
| Glaxosmithkline, LLC. | $62.26 | 2023-2024 | Shingrix, Arexvy, Bexsero |
| Pfizer INC. | $59.86 | 2019-2025 | |
| Lilly USA, LLC | $52.11 | 2019-2024 | Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $42.51 | 2020-2021 | |
| Boston Scientific Corporation | $41.36 | 2020-2025 | Wavewriter Alpha Prime 16 |
| Dexcom, INC. | $38.74 | 2024-2025 | Dexcom G6 Transmitter |
| Ironshore Pharmaceuticals INC. | $35.77 | 2019 | |
| Merck Sharp & Dohme LLC | $33.72 | 2019-2024 | Dificid |
| Vanda Pharmaceuticals INC. | $24.67 | 2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $24.16 | 2019 | |
| Xeris Pharmaceuticals, INC. | $23.07 | 2025 | Keveyis |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $22.38 | 2024 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $21.69 | 2019 | |
| Phadia US INC. | $20.32 | 2024 | Immunocap |
| Shire North American Group INC | $17.07 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $15.96 | 2024 | Opsumit, Uptravi |
| Amgen INC. | $15.01 | 2019 | |
| Exact Sciences Corporation | $14.83 | 2024 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $12.72 | 2023 | Seglentis, Livalo |
| Astrazeneca Pharmaceuticals Lp | $12.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cara Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.